title: Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
abstract: Increased knowledge of molecular alterations involved in gastric carcinogenesis has provided useful information for diagnosis and prediction. In this study, we investigated the clinicopathological significance of TFF3 expression and Her-2/neu status in gastric adenocarcinoma and explored the correlation between TFF3 expression and Her-2/neu status. A hundred and twenty-six (126) patients having undergone curative gastrectomy were enrolled. Immunohistochemistry for TFF3 was performed on tumor tissues and non-neoplastic resection margins. Her-2/neu status was assessed by immunohistochemical staining and fluorescence in situ hybridization (FISH) on tumor tissues. As a result, TFF3 expression and Her-2/neu positivity were detected in 46.8% and 11.9% of the cases, respectively. Patients with negative TFF3 exhibited longer survival than the positive group (P=0.0142), while patients with positive Her-2/neu only showed a tendency toward longer overall survival (P>0.05). However, Her-2/neu was significantly associated with improved disease-free survival (P=0.0234). Multivariate analysis demonstrated Her-2/neu and TFF3 to be independent prognostic indicators of recurrence, and a significantly poor prognosis for expression of TFF3 in patients with Her-2/neu negative tumors. TFF3 is an independent indicator for overall survival in gastric cancer, while Her-2/neu, as a marker of long time survival prediction, seems to be limited.
authors.affiliation: Department of Oncology, The Affiliated Hospital of Medical College, Qingdao University, 16 Jiangsu Road, Qingdao 266003, China.
authors.forename: Cong-cong
authors.initials: CC
authors.lastname: Xu
authors.forename: Lu
authors.initials: L
authors.lastname: Yue
authors.forename: Hong-jun
authors.initials: HJ
authors.lastname: Wei
authors.forename: Wen-wen
authors.initials: WW
authors.lastname: Zhao
authors.forename: Ai-hua
authors.initials: AH
authors.lastname: Sui
authors.forename: Xiu-mei
authors.initials: XM
authors.lastname: Wang
authors.forename: Wen-sheng
authors.initials: WS
authors.lastname: Qiu
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010455:Peptides / Q000032:analysis*; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016896:Treatment Outcome; D000071165:Trefoil Factor-3
chemical_list: D014408:Biomarkers, Tumor; D010455:Peptides; D018719:Erb-b2 Receptor Tyrosine Kinases; D000071165:Trefoil Factor-3; C082495:TFF3 protein, human; C508053:ERBB2 protein, human
keywords: Gastric cancer; Her-2/neu; Prognosis; TFF3